The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
The circular RNA ciRS-7 (Cdr1as) acts as a risk factor of hepatic microvascular invasion in hepatocellular carcinoma
Open accessAbstract
PURPOSE: Circular RNAs (circRNA) represent a novel class of widespread and diverse endogenous RNAs that regulate gene expression in mammals. microRNA-7 (miR-7) is a well-demonstrated suppressor of hepatocellular carcinoma (HCC). Recent studies have showed that one such circRNA, ciRS-7 (also termed as Cdr1as) was the inhibitor and sponge of miR-7 in the embryonic zebrafish midbrain and islet cells. However, the relationships among ciRS-7, miR-7 and clinical features of HCC remain to be clarified. METHODS: Expression levels of ciRS-7, miR-7 and three miR-7-targeted mRNAs in 108 pairs of HCC and their matched non-tumor tissues were examined by quantitative reverse transcription polymerase chain reaction (qRT-PCR). The protein production of these three miR-7-targeted mRNAs was further verified by Western blot. The relationship between ciRS-7 level and clinicopathological features as well as the recurrence of HCC patients was analyzed. The univariate and multivariate logistic regression analyses were used to detect the risk factors of hepatic microvascular invasion (MVI). The correlation among ciRS-7, miR-7 and miR-7-targeted mRNAs was evaluated using Spearman's correlation test. RESULTS: There was no significant difference of ciRS-7 expression levels between the HCC tissues and the matched non-tumor tissues (0.67 ± 1.49 vs. 0.44 ± 0.45, p = 0.13), and the ciRS-7 levels in more than half of HCC tissues (65 out of 108, 60.2 %) were down-regulated when compared with their matched non-tumor tissues. However, the expression of ciRS-7 was significantly correlated with the following three clinicopathological characteristics of HCC patients: age <40 years (p = 0.02), serum AFP ≥400 ng/µl (p < 0.01) and hepatic MVI (p = 0.03). Meanwhile, up-regulated ciRS-7 expression was not only an independent risk factor of hepatic MVI but also had a capable predictive ability for MVI (AUC = 0.68, p = 0.001) at the cut-off value of 0.135. Furthermore, the expression of ciRS-7 in HCC tissues with concurrent MVI was inversely correlated with that of miR-7 (r = -0.39, p = 0.007) and positively related with that of two miR-7-targeted genes [PIK3CD (r = 0.55, p < 0.001) and p70S6K (r = 0.34, p = 0.021)]. In addition, the median recurrent time of patients from higher ciRS-7 level group was shorter than that of lower ciRS-7 group (18 vs. 25 months), but no significant difference was observed (p = 0.38). CONCLUSIONS: The expression levels of ciRS-7 were comparable between HCC and matched non-tumor tissues. However, the highly ciRS-7 expression in HCC tissues was significantly correlated with hepatic MVI, AFP level and younger age and thus partly related with the deterioration of HCC. Especially, ciRS-7 was one of the independent factors of hepatic MVI. These data suggested that ciRS-7 may be a promising biomarker of hepatic MVI and a novel therapy target for restraining MVI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yu, L., Gong, X., Sun, L., Zhou, Q., Lu, B., & Zhu, L. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158347 · Cited by 356
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Circular RNAs are a large class of animal RNAs with regulatory potency
Memczak, S., Jens, M., Elefsinioti, A., Torti, F., Krueger, J., Rybak, A., Maier, L., Mackowiak, S. D., Gregersen, L. H., Munschauer, M., et al. (2013) · Nature · doi:10.1038/nature11928 · Cited by 7,990
Natural RNA circles function as efficient microRNA sponges
Hansen, T. B., Jensen, T. I., Clausen, B. H., Bramsen, J. B., Finsen, B., Damgaard, C. K., & Kjems, J. (2013) · Nature · doi:10.1038/nature11993 · Cited by 7,985
Identification of Novel Genes Coding for Small Expressed RNAs
Lagos-Quintana, M., Rauhut, R., Lendeckel, W., & Tuschl, T. (2001) · Science · doi:10.1126/science.1064921 · Cited by 4,956
Llovet, J. M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., & Gores, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.18 · Cited by 2,531
Salzman, J., Gawad, C., Wang, P. L., Lacayo, N., & Brown, P. O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030733 · Cited by 2,239
Imamura, H., Matsuyama, Y., Tanaka, E., Ohkubo, T., Hasegawa, K., Miyagawa, S., Sugawara, Y., Minagawa, M., Takayama, T., Kawasaki, S., et al. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00360-4 · Cited by 1,589
RNA integrity and the effect on the real-time qRT-PCR performance
Fleige, S., & Pfaffl, M. W. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2005.12.003 · Cited by 1,487
Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells
HSU, M.-T., & COCA-PRADOS, M. (1979) · Nature · doi:10.1038/280339a0 · Cited by 1,021
miRNA‐dependent gene silencing involving Ago2‐mediated cleavage of a circular antisense RNA
Hansen, T. B., Wiklund, E. D., Bramsen, J. B., Villadsen, S. B., Statham, A. L., Clark, S. J., & Kjems, J. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.359 · Cited by 991
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
Roayaie, S., Blume, I. N., Thung, S. N., Guido, M., Fiel, M., Hiotis, S., Labow, D. M., Llovet, J. M., & Schwartz, M. E. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.003 · Cited by 660
Rodríguez-Perálvarez, M., Luong, T. V., Andreana, L., Meyer, T., Dhillon, A. P., & Burroughs, A. K. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2513-1 · Cited by 657
Kefas, B., Godlewski, J., Comeau, L., Li, Y., Abounader, R., Hawkinson, M., Lee, J., Fine, H., Chiocca, E. A., Lawler, S., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6639 · Cited by 647
Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/β-catenin pathway
Li, F., Zhang, L., Li, W., Deng, J., Zheng, J., An, M., Lu, J., & Zhou, Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3469 · Cited by 637
Lei, Z., Li, J., Wu, D., Xia, Y., Wang, Q., Si, A., Wang, K., Wan, X., Lau, W. Y., Wu, M., et al. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2015.4257 · Cited by 599
Xu, H., Guo, S., Li, W., & Yu, P. (2015) · Scientific Reports · doi:10.1038/srep12453 · Cited by 534
Lim, K.-C., Chow, P. K.-H., Allen, J. C., Chia, G.-S., Lim, M., Cheow, P.-C., Chung, A. Y. F., Ooi, L. L. P., & Tan, S.-B. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31821ad884 · Cited by 515
Fang, Y., Xue, J.-L., Shen, Q., Chen, J., & Tian, L. (2012) · Hepatology · doi:10.1002/hep.25576 · Cited by 425
Oka, H., Tamori, A., Kuroki, T., Kobayashi, K., & Yamamoto, S. (1994) · Hepatology · doi:10.1002/hep.1840190111 · Cited by 370
Zhang, H., Cai, K., Wang, J., Wang, X., Cheng, K., Shi, F., Jiang, L., Zhang, Y., & Dou, J. (2014) · Stem Cells · doi:10.1002/stem.1795 · Cited by 368
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Matter, M. S., Decaens, T., Andersen, J. B., & Thorgeirsson, S. S. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.11.031 · Cited by 314
Liu, Q., Zhang, X., Hu, X., Dai, L., Fu, X., Zhang, J., & Ao, Y. (2016) · Scientific Reports · doi:10.1038/srep22572 · Cited by 301
Zimmerman, M. A. (2008) · Archives of Surgery · doi:10.1001/archsurg.2007.39 · Cited by 278
The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma
Zhou, L., Huang, Y., Li, J., & Wang, Z. (2010) · Medical Oncology · doi:10.1007/s12032-009-9201-4 · Cited by 225
Jiang, L., Liu, X., Chen, Z., Jin, Y., Heidbreder, C. E., Kolokythas, A., Wang, A., Dai, Y., & Zhou, X. (2010) · Biochemical Journal · doi:10.1042/bj20100859 · Cited by 205
Saydam, O., Senol, O., Wurdinger, T. D., Mizrak, A., Ozdener, G. B., Stemmer-Rachamimov, A. O., Yi, M., Stephens, R. M., Krichevsky, A. M., Saydam, N., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1219 · Cited by 147
Poon, R. T. P. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0330-y · Cited by 127
Zhang, X., Hu, S., Zhang, X., Wang, L., Zhang, X., Yan, B., Zhao, J., Yang, A., & Zhang, R. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.095 · Cited by 117
Vora, S., Zheng, H., Stadler, Z. K., Fuchs, C. S., & Zhu, A. X. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0038 · Cited by 114
Inflammation-induced repression of tumor suppressor miR-7 in gastric tumor cells
Kong, D., Ys, P., Yamashita, S., Oshima, H., Oguma, K., Fushida, S., Fujimura, T., Minamoto, T., Seno, H., Yamada, Y., et al. (2011) · Oncogene · doi:10.1038/onc.2011.558 · Cited by 111
Yau, T. C. C., Yao, T., Chan, P., Wong, H., Pang, R. W. C., Fan, S. T., & Poon, R. T. P. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0105 · Cited by 109
Liu, S., Zhang, P., Chen, Z., Liu, M., Li, X., & Tang, H. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.05.054 · Cited by 108
Golfieri, R., Bilbao, J. I., Carpanese, L., Cianni, R., Gasparini, D., Ezziddin, S., Paprottka, P. M., Fiore, F., Cappelli, A., Rodríguez‐Fraile, M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.025 · Cited by 98
Ma, C., Qi, Y., Shao, L., Liu, M., Li, X., & Tang, H. (2013) · IUBMB Life · doi:10.1002/iub.1231 · Cited by 54
Li, J., Zheng, Y., Sun, G., & Xiong, S. (2014) · Oncology Reports · doi:10.3892/or.2014.3519 · Cited by 44
mTOR in Viral Hepatitis and Hepatocellular Carcinoma: Function and Treatment
Wang, Z., Jin, W., Jin, H., & Wang, X. (2014) · BioMed Research International · doi:10.1155/2014/735672 · Cited by 32
Cited by
CircRNA: functions and properties of a novel potential biomarker for cancer
Meng, S., Zhou, H., Feng, Z., Xu, Z., Tang, Y., Li, P., & Wu, M. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0663-2 · Cited by 1,521
Circular RNAs in cancer: opportunities and challenges in the field
Kristensen, L. S., Hansen, T. B., Venø, M. T., & Kjems, J. (2018) · Oncogene · doi:10.1038/onc.2017.361 · Cited by 1,326
Circular RNAs function as ceRNAs to regulate and control human cancer progression
Zhong, Y., Du, Y., Yang, X., Mo, Y., Fan, C., Xiong, F., Ren, D., Ye, X., Li, C., Wang, Y., et al. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0827-8 · Cited by 1,007
Circular RNA and its mechanisms in disease: From the bench to the clinic
Han, B., Chao, J., & Yao, H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.010 · Cited by 788
Circular RNAs: Promising Biomarkers for Human Diseases
Zhang, Z., Yang, T., & Xiao, J. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.07.036 · Cited by 775
Metadata
- Authors
- Xu, L., Zhang, M., Zheng, X., Yi, P., Lan, C., & Xu, M.
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2016-09-10
- Volume
- 143
- Issue
- 1
- Pages
- 17-27
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- OpenAlex
- W2514180887
- Cited by
- 301
- References
- 38
- FWCI
- 25.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.